Sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 sub-variant. Sotrovimab is unlikely to be effective against the BA.2 sub-variant. Sotrovimab may not be administered for treatment of COVID-19 under the Emergency Use Authorization until further notice by the U.S. Food and Drug Administration (FDA). Sotrovimab will no longer be allocated to Wyoming and will no longer be available for providers to order from the Wyoming Department of Health (WDH). Further information can be found here: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization.

The Centers for Disease Control and Prevention (CDC) estimate that 52.7% of cases in Region 8, which includes Wyoming, are due to the Omicron BA.2 sub-variant. CDC publishes data on variant proportions here: https://covid.cdc.gov/covid-data-tracker/#variant-proportions

WDH recommends providers store any current supplies of sotrovimab to be prepared if this medication is re-authorized when and if the Omicron BA.2 sub-variant is no longer dominant.

Other medications for the outpatient treatment of COVID-19 among patients at high risk for developing severe COVID-19 illness remain available. The National Institutes of Health (NIH) recommend ritonavir-boosted nirmatrelvir (PAXLOVID) and Remdesivir as the preferred treatments. Bebtelovimab and Molnupiravir are also available but should be used only if the preferred treatments are not available, feasible to use, or clinically appropriate. Based on current medication supply and case burden, providers should consider the preferred therapies for any patient meeting the FDA Emergency Use Authorization or Approval criteria. Recommendations from the NIH can be found here: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/
WDH Supplemental HAN 14.6 COVID-19 April 6, 2022

WDH is enrolling additional providers to receive the outpatient therapeutics PAXLOVID, Molnupiravir, and Bebtelovimab. WDH is also enrolling providers to receive the pre-exposure prophylaxis medication EVUSHELD. Providers can request to be added to the Health Partner Ordering Platform (HPOP) to request therapeutics from Wyoming’s allocation by filling out the HPOP Therapeutic Provider Request Form (https://docs.google.com/forms/d/e/1FAIpQLSfV879fHBL2DMIg-sq3OCKF_Ha29AhOtwwym4NBZJKUP28UuG/viewform). For any questions or additional information please email wdh-therapeutics@wyo.gov.

Further information including links to the most current authorization criteria and healthcare provider fact sheets for COVID-19 therapeutics can be found here: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

**CLINICAL RESOURCES**


CDC’s Clinical Outreach and Communication Activity (COCA) calls and webinars offer the most up to date information and guidance for clinicians. COCA calls can be accessed at https://emergency.cdc.gov/coca/calls/index.asp. The Wyoming Medical Society website contains clinical resources from the University of Washington, including treatment guidelines and algorithms: https://www.wyomed.org/resources/covid-19/.

**CONTACT INFORMATION**

For questions about COVID-19 therapeutics, please contact wdh.covid19@wyo.gov.

Wyoming healthcare providers and facilities are reminded to check COVID-19 resources available from WDH and CDC. Healthcare providers or facilities can contact WDH through the following channels:

- Please email questions about preparedness, PPE, infection control, or other non-urgent topics to wdh.covid19@wyo.gov.
- Please contact WPHL with questions about specimen collection, storage, or shipping at 307-777-7431 or WPHL@wyo.gov.
- **Please use the WDH Public Health Emergency Line (1-888-996-9104) for urgent questions. This line is intended ONLY for healthcare providers. Do not share this number with the public.**

Please refer questions from the general public to 211 or to the WDH email box (wdh.covid19@wyo.gov).